PCSA Processa Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1533743 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,393.5%
TTM EPS YoY34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-203.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets1.0%
Debt / equity—
Current ratio97.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.07x
Accruals ratio-189.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.81M | $649,877 | $1.81M | $2.11M | $1.66M | $2.45M | $1.59M | $1.71M |
| SG&A expense | $4.29M | $1.69M | $1.52M | $1.59M | $1.83M | $1.50M | $1.26M | $1.02M |
| Operating income | -$184.13M | -$2.34M | -$3.33M | -$3.70M | -$3.49M | -$3.95M | -$2.85M | -$2.73M |
| Pretax income | — | — | -$3.38M | — | — | — | -$2.83M | — |
| Net income | -$183.16M | -$3.27M | -$3.38M | -$3.36M | -$3.44M | -$3.93M | -$2.83M | -$2.73M |
| EBITDA | -$184.13M | -$2.34M | -$3.33M | -$3.70M | -$3.49M | -$3.95M | -$2.85M | -$2.73M |
| EPS (basic) | -61.58 | -1.19 | -1.29 | — | -1.81 | -6.26 | -7.58 | — |
| EPS (diluted) | -61.58 | -1.19 | -1.29 | — | -1.81 | -6.26 | -7.58 | — |
| Weighted avg. shares (diluted) | 2.97M | 2.75M | 2.62M | — | 1.90M | 628,796 | 373,967 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $180.21M | $196,325 | $1.69M | $5.54M | $6.31M | $6.94M | $2.90M | $1.19M |
| Current assets | $182.01M | $2.07M | $1.94M | $5.67M | $6.59M | $7.15M | $3.76M | $1.88M |
| PP&E, net | $3,000 | $3,210 | $3,511 | $4,000 | $4,113 | — | — | $5,016 |
| Total assets | $182.01M | $2.07M | $4.52M | $7.81M | $7.58M | $8.18M | $4.81M | $3.23M |
| Current liabilities | $1.86M | $2.39M | $1.98M | $2.24M | $1.75M | $2.07M | $1.28M | $1.53M |
| Total liabilities | $1.86M | $2.39M | $1.98M | $2.24M | $1.75M | $2.07M | $1.28M | $1.53M |
| Shareholders' equity | -$181.38M | -$318,000 | $2.54M | $5.58M | $5.83M | $6.11M | $3.53M | $1.70M |
| Shares outstanding | 2.80M | 2.79M | 2.68M | 2.57M | 52.86M | 40.28M | 5.27M | 148,108 |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.18M | -$2.00M | -$3.59M | -$2.90M | -$3.48M | -$2.27M | -$2.73M | -$2.25M |
| Capital expenditure | — | — | — | — | — | — | — | $0 |
| Free cash flow | — | — | — | — | — | — | — | -$2.25M |
| Investing cash flow | -$1.90M | $186,000 | -$500,000 | — | — | — | — | $0 |
| Financing cash flow | $187.13M | $315,167 | $244,783 | $2.98M | $2.86M | $6.31M | $4.44M | $547,582 |
| Depreciation & amortization | $398 | $301 | $301 | $301 | $301 | $301 | $301 | $301 |
| Stock-based compensation | $846,000 | $92,105 | $95,963 | $123,541 | $303,000 | $203,251 | $227,711 | $155,048 |
Free plan shows the latest 8 periods; Pro shows all 58 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.